# Mesalazine

## Asacol 500mg suppository

##### 臨採

| TAH Drug Code      | [EASA](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=EASA)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of mildly to moderately active ulcerative proctitis, colitis, or proctosigmoiditis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Dosing             | 1-2 suppository TID, after a bowel movement. The dose depends on the response.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Patients with known or suspected hypersensitivity to salicylates or aminosalicylates or to any ingredients in the suppository vehicle. Severe renal impairment: eGFR<30mL/min/1.73m2. Severe liver impairment. Age <2 years.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Adverse Effects    | Common Dermatologic: Rash (Up to 6% ; pediatrics, 5% ) Gastrointestinal: Abdominal pain (Adult, 2.2% to 18% ; pediatrics 5% or more ), Burping (16% ), Diarrhea (Adults, up to 8% ; pediatrics, 5% ), Nausea (Up to 4% ), Vomiting (Less than 1% to 5% ; pediatric, 5% or more ) Musculoskeletal: Arthralgia (Less than 3% to greater than 5% ) Neurologic: Asthenia (Less than 1% to greater than 5% ), Headache (Adults, 2.9% to 14% ; pediatrics, 5% or more ) Respiratory: Nasopharyngitis (Adults, 1.4% to 4% ; pediatrics, 15% ), Rhinitis (5% or more ) Other: Pain (Up to 14% ) Serious Cardiovascular: Myocarditis, Pericarditis Dermatologic: Generalized exanthematous pustulosis, acute, Stevens-Johnson syndrome, Toxic epidermal necrolysis Gastrointestinal: Exacerbation of ulcerative colitis (Pediatrics, 12% ), Gastrointestinal hemorrhage (2% or greater ), Pancreatitis (Less than 1% ), Rectal hemorrhage (Less than 3% to 2% or greater.) Hematologic: Agranulocytosis, Aplastic anemia, Leukopenia, Neutropenia, Pancytopenia, Thrombocytopenia (Less than 1% ) Hepatic: Cholestatic hepatitis (Less than 3% ), Hepatotoxicity, Liver failure, Sclerosing cholangitis Immunologic: Anaphylaxis, Angioedema, Drug reaction with eosinophilia and systemic symptoms, Edema of face (Less than 1% ), Hypersensitivity reaction Renal: Renal impairment Other: Infectious disease, Intolerance to drug, Syndrome |
| Pregnancy          | Human Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

## Colasa enema 2gm/100mL

| TAH Drug Code      | [ECOL2](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ECOL2)                                                                                           |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis, or proctitis                                                                  |
| Dosing             | 2-4 gm (1 to 2 bottles) at night.                                                                                                                                |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                    |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                    |
| Contraindications  | Hypersensitivity to mesalamine, salicylates, or any component of the formulation; severe renal impairment (GFR <30 mL/minute/1.73 m2); severe hepatic impairment |
| Adverse Effects    | Nausea, diarrhea, abdominal pain, headache                                                                                                                       |
| Pregnancy          | Compatible                                                                                                                                                       |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                    |

## MezaVant XL 1200mg prolonged release

| TAH Drug Code      | [OMEZA](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OMEZA)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of moderately active ulcerative colitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Dosing             | 2.4 to 4.8g (2 to 4 tablets) QD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Contraindications  | U.S. labeling: Hypersensitivity to mesalamine, aminosalicylates, salicylates, or any component of the formulation (including suppository vehicle of vegetable fatty acid esters) Canadian labeling: Hypersensitivity to mesalamine, salicylates, or any component of the formulation; severe renal impairment (GFR <30 mL/minute/1.73 m2); severe hepatic impairment Additional contraindications per specific Canadian product labeling: Existing gastric or duodenal ulcer, urinary tract obstruction, use in children <2 years of age (Asacol, Asacol 800, Mesasal, Pentasa, Salofalk); hemorrhagic diathesis (Mesasal); patients unable to swallow intact tablet (Asacol, Asacol 800); renal parenchymal disease (Pentasa) |
| Adverse Effects    | >10%: Central nervous system: Headache (2% to 35%), pain (?14%) Gastrointestinal: Abdominal pain (1% to 18%), eructation (16%), nausea (3% to 13%) Respiratory: Pharyngitis (11%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Pregnancy          | Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

